UBS Group’s Marrone Bio Innovations, Inc. MBII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-438
| Closed | -$1K | – | 11817 |
|
|
2022
Q2 | $1K | Sell |
438
-623,253
| -100% | -$651K | ﹤0.01% | 10203 |
|
|
2022
Q1 | $674K | Sell |
623,691
-7,827
| -1% | -$5.91K | ﹤0.01% | 4460 |
|
|
2021
Q4 | $455K | Buy |
631,518
+598,182
| +1,794% | +$484K | ﹤0.01% | 5051 |
|
|
2021
Q3 | $30K | Sell |
33,336
-24,577
| -42% | -$29.6K | ﹤0.01% | 6770 |
|
|
2021
Q2 | $96K | Buy |
57,913
+41,390
| +250% | +$69.2K | ﹤0.01% | 5916 |
|
|
2021
Q1 | $35K | Sell |
16,523
-5,511
| -25% | -$11.4K | ﹤0.01% | 6889 |
|
|
2020
Q4 | $28K | Buy |
22,034
+6,574
| +43% | +$7.84K | ﹤0.01% | 6710 |
|
|
2020
Q3 | $19K | Sell |
15,460
-7,848
| -34% | -$9.54K | ﹤0.01% | 6370 |
|
|
2020
Q2 | $27K | Sell |
23,308
-6,846
| -23% | -$6.33K | ﹤0.01% | 6361 |
|
|
2020
Q1 | $25K | Sell |
30,154
-44,428
| -60% | -$47.1K | ﹤0.01% | 6360 |
|
|
2019
Q4 | $75K | Buy |
74,582
+34,895
| +88% | +$42.3K | ﹤0.01% | 6144 |
|
|
2019
Q3 | $56K | Buy |
39,687
+30,217
| +319% | +$42.7K | ﹤0.01% | 6142 |
|
|
2019
Q2 | $14K | Sell |
9,470
-21,780
| -70% | -$33.7K | ﹤0.01% | 6870 |
|
|
2019
Q1 | $48K | Buy |
31,250
+2,690
| +9% | +$4.1K | ﹤0.01% | 5576 |
|
|
2018
Q4 | $42K | Buy |
28,560
+15,419
| +117% | +$23.6K | ﹤0.01% | 6257 |
|
|
2018
Q3 | $24K | Buy |
13,141
+6,778
| +107% | +$13.1K | ﹤0.01% | 6709 |
|
|
2018
Q2 | $12K | Buy |
6,363
+3,562
| +127% | +$6.63K | ﹤0.01% | 7058 |
|
|
2018
Q1 | $6K | Sell |
2,801
-1,115
| -28% | -$1.5K | ﹤0.01% | 7181 |
|
|
2017
Q4 | $4K | Sell |
3,916
-3,825
| -49% | -$3.91K | ﹤0.01% | 7486 |
|
|
2017
Q3 | $9K | Buy |
7,741
+3,900
| +102% | +$4.44K | ﹤0.01% | 6966 |
|
|
2017
Q2 | $5K | Buy |
3,841
+425
| +12% | +$603 | ﹤0.01% | 7148 |
|
|
2017
Q1 | $7K | Buy |
+3,416
| New | +$7.24K | ﹤0.01% | 6844 |
|
|
2016
Q4 | – | Sell |
-200
| Closed | – | – | 8145 |
|
|
2016
Q3 | $0 | Sell |
200
-3,160
| -94% | -$3.84K | ﹤0.01% | 8051 |
|
|
2016
Q2 | $3K | Buy |
+3,360
| New | +$2.6K | ﹤0.01% | 7363 |
|
|
2016
Q1 | – | Sell |
-634
| Closed | -$1K | – | 8375 |
|
|
2015
Q4 | $1K | Sell |
634
-6,771
| -91% | -$14.5K | ﹤0.01% | 8200 |
|
|
2015
Q3 | $16K | Buy |
+7,405
| New | +$14.4K | ﹤0.01% | 6927 |
|
|
2015
Q1 | – | Sell |
-492
| Closed | -$2K | – | 9578 |
|
|
2014
Q4 | $2K | Buy |
+492
| New | +$1.3K | ﹤0.01% | 9443 |
|
UBS Group's MBII Position: Q3 2022 in Review
UBS Group sold out of Marrone Bio Innovations, Inc. (MBII) in Q3 2022, closing a stake of 438 shares — an estimated $1K sold.
UBS Group first reported a position in MBII in Q4 2014 and held it in 27 quarters. The position peaked at $674K in Q1 2022. 0 funds tracked by Wall St. Rank hold MBII as of Q3 2022.
- UBS Group reported no remaining Marrone Bio Innovations, Inc. position as of Q3 2022 after selling out during the quarter.
- UBS Group sold 438 Marrone Bio Innovations, Inc. shares in Q3 2022, an estimated $1K.
- UBS Group first reported a position in Marrone Bio Innovations, Inc. in Q4 2014 and held it in 27 quarters.
- UBS Group's Marrone Bio Innovations, Inc. position peaked at $674K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Marrone Bio Innovations, Inc. as of Q3 2022.
Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.